Today's Issue

Main Topic: How drug trials actually work from animal testing to human phases, the systematic problems that bias the results at every stage, what publication bias means for the drugs you take, and what is being done about it

Abstract: Drug development follows a standard pathway: preclinical testing (in vitro cell studies and in vivo animal studies), followed by Phase I (safety in small human groups), Phase II (efficacy in medium groups), Phase III (large-scale efficacy and safety), and post-market surveillance. The overall clinical failure rate is 92%, with most failures due to lack of efficacy or unexpected toxicity not detected in animal models. Only 37% of highly cited animal research translates to human randomized trials, and only 8% of basic science discoveries enter routine clinical use within 20 years. Publication bias is endemic: only 5% of animal studies in the literature had credible positive effects with no hint of bias (Ioannidis, Stanford). In investigator brochures submitted to regulators, only 4% of animal studies showed negative results, and fewer than 20% used basic bias-reduction techniques like randomization and blinding. In April 2026, the FDA reminded more than 2,200 sponsors and researchers of their legal requirement to disclose clinical trial results, citing systematic failure to report negative outcomes. Selective outcome reporting, where trials are registered with one primary outcome and published reporting another, affects an estimated 30-40% of trials. The FDA's own roadmap acknowledges that the majority of drug development failures are due to issues not evident in animal tests.

Trade the Majors

The biggest major of the year is this weekend — and with Kalshi, you don't just watch it. You trade it.

Take a position on who wins, who makes the cut, and how the leaderboard shakes out. With Kalshi, you buy "Yes" or "No" shares based on what you think happens — and earn returns if you're right.

No house. Peer-to-peer. Transparent market pricing. Cash out before the final round if you want.

The markets are live. To get you started, we're giving you a free $10. No deposit, no catch.

The biggest moments in golf. Now they're tradeable.

Claim your $10 and start trading now.

_{Trade responsibly.}

1. How the Process Is Supposed to Work 🔬📋

Every drug approved for human use has passed through the same basic pipeline.

Preclinical testing comes first. The drug is tested in cell cultures in a lab, then in animals, typically mice and rats, sometimes larger animals like dogs or primates. The goal is to establish basic safety and identify whether the drug does what it is supposed to do before any human is exposed.

If preclinical results are promising, the developer applies to begin human trials.

Phase I involves a small group of healthy volunteers, typically 20 to 100 people. The primary question is safety: does the drug cause harm at various doses, and how does the body process it?

Phase II expands to several hundred patients with the target condition. The question shifts to efficacy: does it actually work?

Phase III is the large-scale trial, often thousands of patients across multiple sites, designed to confirm efficacy, monitor side effects, and compare the drug against existing treatments or placebo.

After approval, post-market surveillance is supposed to catch problems that emerge when millions of people use the drug in real-world conditions.

2. The Animal Testing Problem Nobody Wants to Talk About 🐀⚠️

Animal testing is the foundation of the entire system.

The reasons why animal studies can be misleading include differences in biology and physiology between species, poor experimental design and reporting, publication bias, and overinterpretation of results.

But the deeper problem is what gets reported.

The reporting of animal studies is biased, inflating the efficacy of drug candidates and pushing them into the clinic before they are ready.

Of the more than 700 animal studies found in investigator brochures submitted to regulators, only 4% did NOT show positive effects of treatment.

Think about what that means.

The documents regulators use to decide whether to allow human trials contain animal study data in which 96% of results are positive. In the real world of science, that is not what a balanced evidence base looks like.

3. What Happens in Human Trials That the Public Never Hears About 👥🔒

Human trials have their own set of structural problems.

Inclusion and exclusion criteria mean that the people in clinical trials are often not representative of the people who will eventually take the drug.

Trials routinely exclude older adults, people with multiple conditions, pregnant women, and people on other medications. The drug is then approved and prescribed to exactly those populations.

Industry funding bias is well-documented. Studies funded by pharmaceutical companies are significantly more likely to produce positive results than independently funded studies of the same drugs.

The mechanism is not necessarily fraud. It is study design, outcome selection, and what gets published.

Phase IV surveillance is the stage where real-world problems should surface. But post-market surveillance is chronically underfunded and understaffed. Many serious side effects only become known years after approval when enough people have been harmed to create a statistical signal.

Some of the most prescribed drugs in history have been withdrawn after post-market safety signals: Vioxx, Fen-phen, Baycol, thalidomide. Each passed the trial system that was designed to catch exactly these problems.

5. What Is Actually Changing and What Is Not 🔭🔬

The problems described above are not new. They have been documented in peer-reviewed literature for decades.

What is changing: the tools available for testing are genuinely improving.

Organs-on-chips are microfluidic devices lined with human cells that replicate the function of specific organs. The use of more innovative tools such as organs-on-chips in the preclinical pipeline for drug testing has revealed that these tools are more able to predict unexpected safety events prior to clinical trials.

Human organoids (miniature organ structures grown from human stem cells) allow drug testing on human tissue without human subjects.

AI-driven trial design is reducing selective outcome reporting by pre-registering analysis plans before data is collected.

What is not changing: the financial structure of drug development creates incentives to report positive results, move drugs through the pipeline quickly, and avoid publishing failures.

Regulations exist to counteract these incentives. The FDA's April 2026 reminder to 2,200 companies suggests those regulations are not being enforced effectively.

The failure rate for the translation of drugs from animal testing to human treatments remains at over 92%, where it has been for the past few decades.

The tools are getting better. The system surrounding them has not kept pace.

Takeaways

• The drug development pipeline moves from preclinical animal testing to Phase I-III human trials and post-market surveillance; 92% of drugs that pass animal testing fail in human trials due to unexpected toxicity or lack of efficacy, only 37% of highly cited animal research translates to human randomized trials, and only 8% of basic science discoveries enter routine clinical use within 20 years, with the FDA's own roadmap acknowledging that the majority of failures involve problems not evident in animal tests.

• Publication bias systematically distorts the evidence base: only 4% of animal studies in regulatory filings showed negative results, fewer than 20% used basic bias-reduction techniques like randomization and blinding, and in April 2026 the FDA had to remind more than 2,200 companies of their legal requirement to disclose trial results, with selective outcome reporting estimated to affect 30-40% of published clinical trials, meaning the drug that looks effective in the literature may be one whose negative trials were never published.

• Human trial populations are systematically unrepresentative of real-world patients (excluding older adults, people with multiple conditions, and those on other medications), industry-funded studies produce positive results at significantly higher rates than independently funded ones, and post-market surveillance is chronically underfunded, while newer tools including organs-on-chips, human organoids, and AI-driven trial design are genuinely improving predictive accuracy but have not yet changed the financial incentives that drive the system's structural problems.

Finish when you want, not when you have to

Finishing too fast in the bedroom isn't something most guys talk about, but it's super frustrating.

Go Long handles both.

It’s got Tadalafil for harder erections that last up to 36 hours. Plus Paroxetine to help you stay in control of timing, without numbing sprays or messy creams that ruin the moment for everyone.

One pill. Two solutions. Full control over your performance.

Go Long is doctor-prescribed, discreetly delivered, and designed for men who want sex to actually be good.

Get started with Go Long